Reproductive Health · 1960
Enovid: First FDA-Approved Oral Contraceptive Pill
Before 1960, contraception in the United States was a matter of barriers, timing, and chance. The diaphragm and condom were the most reliable available options, both requiring action at the time of intercourse and both with meaningful failure rates. Reliable contraception also required a clinician's involvement in fitting or prescribing, and in several states laws derived from the 1873 Comstock Act still restricted the distribution of contraceptive information or devices. The social and medical demand for something simpler and more effective was enormous, and it found its most consequential expression in the collaboration between Gregory Pincus, John Rock, and Celso Garcia.
Pincus, an endocrinologist at the Worcester Foundation for Experimental Biology, had been approached by Margaret Sanger and the Planned Parenthood Federation, which provided early funding to explore hormonal contraception. He identified progesterone's capacity to suppress ovulation and worked with G.D. Searle and Company to develop synthetic progestins suitable for oral use. Carl Djerassi at Syntex had synthesized norethindrone in 1951, which became the active progestin in the eventual formulation. Rock, a Boston gynecologist, conducted early human trials beginning around 1954. Garcia then organized large-scale field trials in Puerto Rico starting in 1956, enrolling hundreds of women and establishing efficacy and tolerability data sufficient for regulatory submission.
The FDA cleared Searle's Enovid for contraceptive use on June 23, 1960. The initial approved formulation contained approximately 10 mg of norethynodrel and 150 mcg of mestranol, doses considerably higher than later preparations. Within two years of approval, roughly 1.2 million American women were taking it, a rate of adoption without precedent for a prescription product that addressed no acute illness.
The social effects were immediate and contested. Concerns about thromboembolic risk surfaced in the early 1960s, and by 1970 Senator Gaylord Nelson's subcommittee was holding hearings on whether women were being adequately informed of the pill's risks. Those hearings produced a direct consequence in regulatory policy: the FDA required Searle to include a patient package insert detailing the risks and benefits of Enovid in plain language. It was the first such insert mandated for any prescription drug in the United States, and it established a precedent that eventually became standard practice across all drug categories.
Subsequent decades brought progressively lower hormone doses. By the 1980s combined oral contraceptives contained 30 to 35 mcg of ethinyl estradiol rather than the original 150 mcg, substantially reducing the thromboembolic risk without sacrificing efficacy. Progestin-only pills, long-acting hormonal implants, and the hormonal intrauterine device extended the hormonal contraception category far beyond Enovid's original design. The 1960 approval was the regulatory moment from which all of that followed.
Key People
- Gregory Pincus — Endocrinologist who led the biological development of the pill
- John Rock — Gynecologist who co-directed the clinical trials
- Celso Garcia — Obstetrician who ran field trials in Puerto Rico
- Carl Djerassi — Chemist who synthesized norethindrone, the pill's active progestin
- Margaret Sanger — Birth control advocate who funded and motivated Pincus's early research.
FDA approval of Enovid for contraceptive use, 1960
Related landmarks
- 1958 · Diagnostic medical ultrasound for obstetrics and abdominal masses (Donald) (Reproductive Health)
- 1953 · Apgar Score for newborn assessment (Reproductive Health)
- 1968 · Rh Immune Globulin (Anti-D / RhoGAM) for Prevention of Rh Hemolytic Disease (Reproductive Health)
- 1971 · Diethylstilbestrol (DES) and Vaginal Clear-Cell Adenocarcinoma (Reproductive Health)